Skip to main content
OTCMKTS:HBPCF

Helix BioPharma Competitors

$0.76
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.76
$0.76
50-Day Range
$0.67
$0.76
52-Week Range
$0.22
$1.01
VolumeN/A
Average Volume1,665 shs
Market Capitalization$107.80 million
P/E RatioN/A
Dividend YieldN/A
Beta0.04

Competitors

Helix BioPharma (OTCMKTS:HBPCF) Vs. CUE, AKUS, FBRX, PBYI, SPRO, and TXMD

Should you be buying HBPCF stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Helix BioPharma, including Cue Biopharma (CUE), Akouos (AKUS), Forte Biosciences (FBRX), Puma Biotechnology (PBYI), Spero Therapeutics (SPRO), and TherapeuticsMD (TXMD).

Helix BioPharma (OTCMKTS:HBPCF) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Helix BioPharma and Cue Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A$-6,680,000.00N/AN/A
Cue Biopharma$3.46 million124.11$-36,700,000.00($1.66)-8.23

Helix BioPharma has higher earnings, but lower revenue than Cue Biopharma.

Institutional and Insider Ownership

64.5% of Cue Biopharma shares are owned by institutional investors. 7.6% of Helix BioPharma shares are owned by insiders. Comparatively, 9.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings for Helix BioPharma and Cue Biopharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
Cue Biopharma00503.00

Cue Biopharma has a consensus target price of $30.60, suggesting a potential upside of 123.85%. Given Cue Biopharma's higher probable upside, analysts plainly believe Cue Biopharma is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and Cue Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/A-325.42%-193.46%
Cue Biopharma-1,142.70%-63.69%-50.08%

Volatility and Risk

Helix BioPharma has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500.

Summary

Cue Biopharma beats Helix BioPharma on 8 of the 10 factors compared between the two stocks.

Helix BioPharma (OTCMKTS:HBPCF) and Akouos (NASDAQ:AKUS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Helix BioPharma and Akouos' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A$-6,680,000.00N/AN/A
AkouosN/AN/AN/AN/AN/A

Institutional & Insider Ownership

88.7% of Akouos shares are held by institutional investors. 7.6% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Helix BioPharma and Akouos, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
Akouos01402.80

Akouos has a consensus target price of $30.00, suggesting a potential upside of 141.94%. Given Akouos' higher probable upside, analysts clearly believe Akouos is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and Akouos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/A-325.42%-193.46%
AkouosN/AN/AN/A

Summary

Akouos beats Helix BioPharma on 5 of the 6 factors compared between the two stocks.

Helix BioPharma (OTCMKTS:HBPCF) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Helix BioPharma and Forte Biosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A$-6,680,000.00N/AN/A
Forte Biosciences$40,000.0010,677.86$-63,520,000.00($40.33)-0.78

Helix BioPharma has higher earnings, but lower revenue than Forte Biosciences.

Institutional & Insider Ownership

53.0% of Forte Biosciences shares are held by institutional investors. 7.6% of Helix BioPharma shares are held by insiders. Comparatively, 10.9% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Helix BioPharma and Forte Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
Forte Biosciences00803.00

Forte Biosciences has a consensus target price of $80.50, suggesting a potential upside of 154.67%. Given Forte Biosciences' higher probable upside, analysts clearly believe Forte Biosciences is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and Forte Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/A-325.42%-193.46%
Forte BiosciencesN/A-417.87%-248.28%

Risk & Volatility

Helix BioPharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.

Summary

Forte Biosciences beats Helix BioPharma on 6 of the 9 factors compared between the two stocks.

Helix BioPharma (OTCMKTS:HBPCF) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Helix BioPharma and Puma Biotechnology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A$-6,680,000.00N/AN/A
Puma Biotechnology$272.30 million1.52$-75,600,000.00($1.95)-5.26

Helix BioPharma has higher earnings, but lower revenue than Puma Biotechnology.

Institutional & Insider Ownership

87.9% of Puma Biotechnology shares are held by institutional investors. 7.6% of Helix BioPharma shares are held by insiders. Comparatively, 21.2% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Helix BioPharma and Puma Biotechnology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
Puma Biotechnology13102.00

Puma Biotechnology has a consensus target price of $12.40, suggesting a potential upside of 20.98%. Given Puma Biotechnology's higher probable upside, analysts clearly believe Puma Biotechnology is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and Puma Biotechnology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/A-325.42%-193.46%
Puma Biotechnology-23.86%-451.50%-22.80%

Risk & Volatility

Helix BioPharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Summary

Puma Biotechnology beats Helix BioPharma on 7 of the 10 factors compared between the two stocks.

Helix BioPharma (OTCMKTS:HBPCF) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Helix BioPharma and Spero Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A$-6,680,000.00N/AN/A
Spero Therapeutics$18.15 million22.77$-60,920,000.00($3.35)-4.16

Helix BioPharma has higher earnings, but lower revenue than Spero Therapeutics.

Institutional & Insider Ownership

57.6% of Spero Therapeutics shares are held by institutional investors. 7.6% of Helix BioPharma shares are held by insiders. Comparatively, 17.4% of Spero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Helix BioPharma and Spero Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
Spero Therapeutics00503.00

Spero Therapeutics has a consensus target price of $32.75, suggesting a potential upside of 135.10%. Given Spero Therapeutics' higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and Spero Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/A-325.42%-193.46%
Spero Therapeutics-768.15%-93.43%-72.17%

Risk & Volatility

Helix BioPharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Summary

Spero Therapeutics beats Helix BioPharma on 8 of the 10 factors compared between the two stocks.

Helix BioPharma (OTCMKTS:HBPCF) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations.

Valuation and Earnings

This table compares Helix BioPharma and TherapeuticsMD's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A$-6,680,000.00N/AN/A
TherapeuticsMD$49.65 million8.32$-176,150,000.00($0.68)-1.54

Helix BioPharma has higher earnings, but lower revenue than TherapeuticsMD.

Institutional & Insider Ownership

52.6% of TherapeuticsMD shares are held by institutional investors. 7.6% of Helix BioPharma shares are held by insiders. Comparatively, 13.8% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Helix BioPharma and TherapeuticsMD, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helix BioPharma0000N/A
TherapeuticsMD11302.40

TherapeuticsMD has a consensus target price of $5.0667, suggesting a potential upside of 382.54%. Given TherapeuticsMD's higher probable upside, analysts clearly believe TherapeuticsMD is more favorable than Helix BioPharma.

Profitability

This table compares Helix BioPharma and TherapeuticsMD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helix BioPharmaN/A-325.42%-193.46%
TherapeuticsMD-327.98%N/A-78.47%

Risk & Volatility

Helix BioPharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 2.19, meaning that its stock price is 119% more volatile than the S&P 500.

Summary

TherapeuticsMD beats Helix BioPharma on 8 of the 10 factors compared between the two stocks.


Helix BioPharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cue Biopharma logo
CUE
Cue Biopharma
1.3$13.67flat$429.42 million$3.46 million-8.71Earnings Announcement
Upcoming Earnings
Analyst Report
Gap Down
Akouos logo
AKUS
Akouos
1.7$12.40flat$427.17 millionN/A0.00Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$31.61flat$427.11 million$40,000.00-1.37Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.25flat$413.71 million$272.30 million-7.17Gap Down
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$13.93flat$413.23 million$18.15 million-3.28News Coverage
Gap Down
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.05flat$412.85 million$49.65 million-1.48Analyst Upgrade
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$8.24flat$411.27 million$72.96 million-2.67Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.19flat$407.85 million$380,000.000.00Upcoming Earnings
Gap Down
Sesen Bio logo
SESN
Sesen Bio
1.2$2.34flat$405.49 millionN/A-5.32Earnings Announcement
Analyst Downgrade
Analyst Revision
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$11.07flat$397.16 million$58.12 million-12.87High Trading Volume
Evolus logo
EOLS
Evolus
1.5$9.06flat$396.27 million$34.92 million-4.46Analyst Upgrade
Gap Down
DURECT logo
DRRX
DURECT
1.4$1.72flat$391.14 million$29.56 million-34.39Analyst Report
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
1.0$19.42flat$387.37 million$362.21 million23.40
BeyondSpring logo
BYSI
BeyondSpring
1.2$9.75flat$381.63 millionN/A-4.78News Coverage
Athersys logo
ATHX
Athersys
1.3$1.69flat$375.33 million$5.63 million-4.57Gap Down
Oncorus logo
ONCR
Oncorus
1.7$14.51flat$372.18 millionN/A0.00
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$15.84flat$371.83 millionN/A0.00Earnings Announcement
Analyst Revision
Gap Down
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.56flat$370.62 million$3.89 million-3.96Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Homology Medicines logo
FIXX
Homology Medicines
1.6$6.43flat$367.05 million$1.67 million-2.36News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$14.05flat$366.44 millionN/A-2.95Earnings Announcement
Analyst Revision
News Coverage
Gap Up
MedAvail logo
MDVL
MedAvail
1.9$11.35flat$362.59 million$1.03 million-2.78Earnings Announcement
News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.68flat$357.90 million$36.63 million-4.33Upcoming Earnings
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.43flat$357.85 million$9.48 million-0.24Analyst Revision
Gap Down
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$9.68flat$356.67 millionN/A0.00Analyst Revision
News Coverage
Gap Up
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.60flat$356.56 million$16.54 million-3.09Upcoming Earnings
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$15.25flat$355.36 millionN/A0.00Earnings Announcement
News Coverage
BCEL
Atreca
1.7$9.58flat$352.84 millionN/A-3.40Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.4$3.56flat$350.85 million$111.39 million25.43Insider Buying
News Coverage
Gap Down
Atossa Therapeutics logo
ATOS
Atossa Therapeutics
1.2$2.90flat$350.39 millionN/A-2.15Earnings Announcement
Gap Down
GT Biopharma logo
GTBP
GT Biopharma
1.2$12.32flat$349.81 millionN/A0.00Gap Up
Ampio Pharmaceuticals logo
AMPE
Ampio Pharmaceuticals
1.3$1.77flat$346.37 millionN/A-12.64Gap Up
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$1.06flat$346.10 millionN/A-0.30Earnings Announcement
Gap Down
Verona Pharma logo
VRNA
Verona Pharma
1.7$5.92flat$342.98 millionN/A-1.80
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$2.98flat$337.32 million$6.68 million-3.59Earnings Announcement
Analyst Revision
News Coverage
Gap Down
XOMA logo
XOMA
XOMA
1.5$29.92flat$337.20 million$18.37 million-26.95Analyst Revision
Gap Down
Theratechnologies logo
THTX
Theratechnologies
1.1$3.51flat$329.38 million$63.22 million-11.32News Coverage
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$5.06flat$327.09 million$6.07 million-2.42Analyst Report
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$5.22flat$322.90 million$1.98 million-3.14
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$6.41flat$321.81 millionN/A-5.21
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$9.84flat$321.57 millionN/A-3.42
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.7$11.70flat$320.70 millionN/A-8.86Analyst Report
Analyst Revision
News Coverage
Gap Up
UroGen Pharma logo
URGN
UroGen Pharma
1.8$15.20flat$317.63 million$20,000.00-2.37Earnings Announcement
Unusual Options Activity
Analyst Revision
News Coverage
iBio logo
IBIO
iBio
1.3$1.47flat$317.54 million$1.64 million0.00Upcoming Earnings
Gap Up
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$10.30flat$311.35 million$2.71 million-17.76Gap Up
MEI Pharma logo
MEIP
MEI Pharma
1.7$2.76flat$310.75 million$28.91 million-4.60Analyst Revision
News Coverage
Gap Down
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$6.21flat$309.61 million$15.98 million-1.10Earnings Announcement
News Coverage
Gap Down
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.14flat$306.75 millionN/A-4.46
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.30flat$296.48 millionN/A-4.57Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$8.66flat$296.34 million$28.95 million-12.37Earnings Announcement
News Coverage
Gap Down
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$6.22flat$288.58 million$6.29 million-3.57Gap Down
This page was last updated on 5/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.